DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG.
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
J Clin Endocrinol Metab 2009; 94: 386-391
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.